Otonomy Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
February 27, 2020 16:15 ET
|
Otonomy, Inc.
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseCurrent capital funds operations into 2021 Conference call and webcast today at 4:30...
Otonomy to Present at Two Upcoming Investor Conferences
February 24, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
February 20, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Presents Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program
January 28, 2020 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Provides Corporate and Product Pipeline Update
January 09, 2020 07:30 ET
|
Otonomy, Inc.
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) --...
Otonomy to Participate in Two Upcoming Investor Conferences
November 26, 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 05, 2019 16:13 ET
|
Otonomy, Inc.
Results from three clinical trials expected in 2020 including the Phase 3 trial of OTIVIDEX™ in Ménière’s diseaseBroadest pipeline in neurotology field expanded to include gene therapy collaboration...
Otonomy to Present at the Cantor Global Healthcare Conference
September 26, 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 01, 2019 16:20 ET
|
Otonomy, Inc.
Clinical-stage programs on track with results expected from three trials in 2020Current capital funds operations into 2021 Conference call and webcast today at 4:30 p.m. EDT SAN DIEGO, Aug. 01,...
Otonomy to Report Second Quarter 2019 Financial Results and Provide Corporate Update
July 25, 2019 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...